Efficacy of cytokine-induced killer cells on patients with advanced lung cancer
10.3969/j.issn.1000-8179.2016.07.118
- VernacularTitle:细胞因子诱导杀伤细胞治疗晚期肺癌的临床疗效观察
- Author:
Qian LONG
;
Hang ZHOU
;
Jiahui WANG
;
Yuan FENG
;
Ling HUANG
;
Xing ZHOU
;
Jun CHEN
- Publication Type:Journal Article
- Keywords:
cytokine-induced killer cells;
lung cancer;
efficiency;
adverse reaction
- From:
Chinese Journal of Clinical Oncology
2016;43(7):302-305
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of cytokine-induced killer (CIK) cells on patients with advanced lung cancer. Methods:A total of 90 patients with advanced lung cancer were identified from January 2011 to December 2013. CIK therapy was given to 41 pa-tients in the observation group, whereas the other 49 patients in the control group received the best support treatments without che-motherapy or radiotherapy within one month of inclusion. Following up was conducted for the patients in the two groups, and KPS scores, median survival, and adverse reactions compared. Results:The KPS score in the observation group was higher than that of the control group after treatment (P=0.034). The median survival period of the observation group was eight months, which was one month longer than that of the control group (P=0.044). Major adverse reactions included fever, joint pain, and insomnia, which were recorded 51.22%, 36.58%, and 29.27%of occurrence, respectively. Conclusion:CIK cell therapy improved the quality of life and pro-longed the survival of advanced lung cancer patients with tolerable adverse reactions.
